Interaction with Fc gamma RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

Division of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
The Journal of Immunology (Impact Factor: 5.36). 08/2011; 187(4):1754-63. DOI: 10.4049/jimmunol.1101135
Source: PubMed

ABSTRACT A high activatory/inhibitory FcγR binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal FcγR binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and FcγR interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in FcγR knockout mice demonstrated a critical role for the inhibitory FcγRIIB in 3/23 activity, whereas activatory FcγR (FcγRI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of FcγRIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory FcγR provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of FcγRIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory FcγRIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use.

Download full-text


Available from: Mark Cragg, Jul 28, 2015
  • Source
    • "It is therefore possible that in vivo FcR-expressing cells would provide cross-linking stimulus similar to secondary Abs in vitro inducing cell death in the tumor cell. It has been shown that the in vivo activity of the agonistic CD40 mAb depends on cross-linking provided by FcγRIIb demonstrating that cross-linking by FcγRs can be an important mechanism of action of mAb therapy [79] [80]. For CD20 mAb therapy, expression of FcγRs are needed as shown by FcRγ-chain KO mice, but whether this is required for active signaling or whether FcγR are purely serve as a scaffold to provide cross-linking was unclear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are successfully used in the clinic for the depletion of B cells to treat various forms of cancer and autoimmune diseases. The first CD20 mAb, approved by the FDA in 1998, was rituximab (RTX) and since then it has been widely used to treat more than one million patients thus far. The success of RTX has led to a general interest in the mechanism of action of CD20 mAbs. CD20 mAbs can induce tumor killing via various mechanisms, such as direct induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent lysis (CDC). Although we now understand these mechanisms better, it is still unclear which of these mechanisms is the most important for in vivo RTX action. Not every patient respond to RTX treatment and eventually the overwhelming majority will experience a relapse. Therefore, there is an urgent need to improve the efficacy of CD20 mAbs. This review aims to summarize our current understanding on the mechanism of action of CD20 mAbs.
    American Journal of Cancer Research 01/2012; 2(6):676-90. · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The induction of cytokine release is a common consequence of the administration of therapeutic antibodies and in most cases is either tolerated by the patient or can be managed clinically by the administration of corticosteroids. However, in 2006, the administration of TGN1412 to six patients in a Phase I trial resulted in a unprecedentedly high level of cytokine release, systemic organ failure and the hospitalization of the subjects. Whilst the path to failure in this incident was multifactorial, at least one contributing factor was the lack of a robust in vitro model that would allow the prediction of the in vivo activity of a therapeutic antibody. In this article we review the current 'state of the art' of in vitro cytokine release assays and explore potential future developments.
    Bioanalysis 12/2011; 3(23):2657-63. DOI:10.4155/bio.11.272 · 3.03 Impact Factor
  • Medecine sciences: M/S 01/2012; 28(1):11-3. DOI:10.1051/medsci/2012281003 · 0.52 Impact Factor
Show more